Notice of Results

Verona Pharma plc ("Verona Pharma" or the "Company") Notice of Results 05 May 2015, Cardiff - Verona Pharma plc (AIM: VRP), the drug developmentcompany focused on first-in-class medicines to treat respiratory diseases,expects to announce its preliminary results for the year ended 31 December 2014on Tuesday 12 May 2015. -Ends- For further information please contact: Verona Pharma plc Tel: +44 (0)20 3283 4200Jan-Anders Karlsson, Chief Executive Officer FTI Consulting Tel: +44 (0)20 3727 1000Julia Phillips / Simon Conway Notes to Editors About Verona Pharma plc Verona Pharma plc is a UK-based clinical stage biopharmaceutical companyfocused on the development of innovative prescription medicines to treatrespiratory diseases with significant unmet medical needs, such as chronicobstructive pulmonary disease (COPD), asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in PhaseII trials as a nebulised treatment for acute exacerbations of COPD in thehospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor andtherefore has both bronchodilator and anti-inflammatory effects, which areessential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader portfolio of RPL554-containingproducts to maximise its benefit to patients and its value. This includes thevery significant markets for COPD and asthma maintenance therapy. The Companyis also exploring the potential of the drug in different diseases, such ascystic fibrosis, where it is in pre-clinical testing and has recently receiveda Venture and Innovation Award from the Cystic Fibrosis Trust.